Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Investigating the role of Bruton's tyrosine kinase in microglia and remyelination in multiple sclerosis and its animal models
EF 2021-22
Résumé
Multiple sclerosis (MS) is a chronic inflammatory disease characterized by the invasion of immune cells into the brain and spinal cord. These immune cells damage myelin, which is a protective layer surrounding nerve fibres and is important for signal transduction along the nerves. Myelin damage propagates the inflammatory response of immune cells, causing the killing of nerve fibres and the formation of lesions. Recent clinical trials on treatments for MS have focused on inhibiting Brutons tyrosine kinase (BTK), an enzyme that is activated in immune cells, particularly microglia, during inflammation. However, it is unknown how the expression of BTK in these microglia contributes to the pathology of the disease and whether its activation affects the reparative process of lesions.My goal is to explore the role of BTK during inflammation in the spinal cord, and determine whether inhibiting BTK will promote myelin repair. I will investigate the expression of BTK in spinal cords of two different MS mouse models to determine its extent of localization in the lesion and within microglia. To determine whether BTK inhibition can prevent the killing of nerve cells, I will activate microglia in an in vitro environment, inhibit their BTK activity, and observe resulting changes in inflammation and killing. Furthermore, I will administer a BTK inhibitor to one of our mouse models of MS and evaluate whether the drug will yield improvements reducing the extent of inflammation and myelin repair. Improving our understanding of BTK sheds light on its role in inflammatory lesions. As BTK inhibitors have entered clinical trials in MS, my thesis accompanies this development to shed light on the mechanisms and potential therapeutic benefits of BTK inhibitors for individuals living with MS.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466997
Name
Li Cenxiao
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of Bruton's tyrosine kinase in microglia and remyelination in multiple sclerosis and its animal models
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bruton'S Tyrosine Kinase; Microglia; Mouse Models; Multiple Sclerosis; Neuroimmunology; Remyelination
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease characterized by the invasion of immune cells into the brain and spinal cord. These immune cells damage myelin, which is a protective layer surrounding nerve fibres and is important for signal transduction along the nerves. Myelin damage propagates the inflammatory response of immune cells, causing the killing of nerve fibres and the formation of lesions. Recent clinical trials on treatments for MS have focused on inhibiting Brutons tyrosine kinase (BTK), an enzyme that is activated in immune cells, particularly microglia, during inflammation. However, it is unknown how the expression of BTK in these microglia contributes to the pathology of the disease and whether its activation affects the reparative process of lesions.My goal is to explore the role of BTK during inflammation in the spinal cord, and determine whether inhibiting BTK will promote myelin repair. I will investigate the expression of BTK in spinal cords of two different MS mouse models to determine its extent of localization in the lesion and within microglia. To determine whether BTK inhibition can prevent the killing of nerve cells, I will activate microglia in an in vitro environment, inhibit their BTK activity, and observe resulting changes in inflammation and killing. Furthermore, I will administer a BTK inhibitor to one of our mouse models of MS and evaluate whether the drug will yield improvements reducing the extent of inflammation and myelin repair. Improving our understanding of BTK sheds light on its role in inflammatory lesions. As BTK inhibitors have entered clinical trials in MS, my thesis accompanies this development to shed light on the mechanisms and potential therapeutic benefits of BTK inhibitors for individuals living with MS.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Cenxiao
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~